Ulmus Investment
VC Fund
Ulmus Investment is a VC fund focused on Biotechnology and Artificial Intelligence. Ulmus Investment
- Total investments:
- 20
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries Ulmus Investment invests in
BiotechnologyArtificial IntelligenceManufacturingHealth CareTherapeutics
Stages Ulmus Investment invests in
Series ASeries BSeries CFunding RoundPrivate Equity
Countries Ulmus Investment invests in
South KoreaUnited Kingdom
Round sizes
Series A $4.2M–$63MSeries B $5M–$27MSeries C $8.4M–$33M
Round size
- Series A
- $4.2M–$63M
- Series B
- $5M–$27M
- Series C
- $8.4M–$33M
Investment Focus
Industry
- Biotechnology 7 (35%)
- Artificial Intelligence 5 (25%)
- Manufacturing 4 (20%)
- Health Care 3 (15%)
- Therapeutics 3 (15%)
Stage
- Series A 7 (35%)
- Series B 7 (35%)
- Series C 2 (10%)
- Funding Round 2 (10%)
- Private Equity 1 (5%)
Country
- South Korea 15 (75%)
- United Kingdom 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Dnotitia
|
Dnotitia is a pioneering AI (Artificial Intelligence) company driving innovative value by integrating AI and data. Founded in October 2023, Dnotitia specializes in developing; Seahorse, a high-performance vector database powered by its proprietary Vector Data Processing Units (VDPU), and Mnemos, a cutting-edge service solution for Large LanguageModels (LLMs). The company also leads the development of sLMs (Small Language Models) and Retrieval-Augmented Generation (RAG) systems, crucial for advancing generative AI technologies and positioning itself at the forefront of AI technology. | $63.4M / Series A / Apr 21, 2026 | |
Quantum AI
|
Quantum AI is an AI data company that offers offline and online data collection and analysis services. Currently, Quantum AI is providing various services centered on the financial sector, including AI document processing automation, intelligent voice consultation, assetization of unstructured financial data based on its own language model, and AIsearch. Utilizing a proprietary AI recognition engine, the company has integrated and analyzed various data sources, including financial documents, customer consultation history, and market news, and have carried out numerous AI data assetization projects for major domestic commercial banks and insurance companies. | $5M / Series B / Nov 06, 2025 | |
MakinaRocks
|
Founded in December 2017, MakinaRocks is a startup specializing in industrial machine intelligence solutions. The company develops industrial AI solutions and a machine learning platform. MakinaRocks’s solutions mitigate the challenges of industries sites—optimizing production quality and process efficiency of the automotive, energy, semiconductor,and battery sectors. Built for ML engineers, MakinaRocks’s end-to-end ML platform covers integral machine learning and model development processes, enhancing while simplifying the transition to AI. | $12M / Dec 31, 2024 | |
TeraView
|
TeraView is the world’s first company devoted to the application of Terahertz light for imaging and spectroscopy. TeraView’s proprietary platform uses the Terahertz spectrum between light and radio waves and offers the advantage of being non-invasive and non-destructive. A key application of the technology is the detection of faults and qualityvariations in semiconductor integrated circuits. In addition, studies have demonstrated how Terahertz uniquely and non invasively provides 3 dimensional structural and chemical information in a diverse range of applications, including weapons/explosives hidden below clothing, the contents of tablets and capsules in the pharmaceutical industry, and other objects normally invisible to conventional detection techniques. Other markets for the technology exist in medical imaging of cancer and industrial inspection which are explored via commercial partners. Headquartered in Cambridge, UK, TeraView was spun-out of the Toshiba Cambridge Research Laboratory in April 2001. Sales and support are available throughout Europe, North America and the Far East either directly or through a network of distributors. | $7.2M / Private Equity / Nov 29, 2024 | |
Eul Biosciences
|
Eul Bioscience is a life science firm that focuses on stem cell exosomes. Eul Bioscience specializes in creating regenerative aesthetic cosmetics and wound dressings that utilize stem cells and exosomes derived from them. Exosomes have recently gained prominence in areas such as cosmetics and skin boosters, serving as vehicles for substancessecreted by cells in the body to convey information. Specifically, stem cell exosomes transport substances that contribute to anti-aging, tissue regeneration, and the regulation of inflammation and immunity, which are released into adjacent cells. Eul Bioscience operates a hospital platform under the 'Eeul' brand, encompassing plastic surgery, orthopedics, dentistry, ophthalmology, and veterinary clinics. With this foundation, the company has achieved vertical integration of its entire value chain, from the procurement of stem cells to the production of exosomes. This strategy is marked by the careful selection of high-quality stem cells and the guarantee of efficiency during the purchasing process. Eul Bioscience stands out as the sole company in Korea with such a comprehensive value chain. Another notable advantage is its proprietary culture technology, which significantly enhances the volume of exosome secretion. Furthermore, the company is adept at developing customized products that meet the specific requirements of hospitals and clinics. | $11.3M / Series A / Sep 25, 2024 | |
AITRICS
|
AITRICS delivers AI-powered medical software designed to support clinicians in detecting and preventing critical patient deterioration. The company’s core product, AITRICS‑VC (VitalCare), continuously monitors data from electronic medical records (EMRs), including vital signs, lab tests, consciousness levels, and other relevant clinicalmeasurements to predict adverse events such as sepsis, cardiac arrest, unexpected ICU transfers, or mortality several hours before they occur.AITRICS-VC operates in real time, delivering risk scores and alerts to clinicians to enable earlier intervention and better resource allocation in hospital settings. The platform has been certified by the relevant regulatory authority in its home country and is classified as an “innovative medical device,” reflecting regulatory recognition of its predictive-analytics capabilities. In addition to monitoring and prediction, AITRICS engages in ongoing clinical validation and research; it publishes studies in peer-reviewed journals and presents its work in international AI conferences, indicating a commitment to evidence-based development and transparency in performance. | $20.3M / Series B / Mar 21, 2024 | |
Anipen
|
ANIPEN (애니펜) is a Korean 3D content development platform that enables enterprises to develop video communication and entertainment platforms. | $11.9M / Series B / Oct 17, 2022 | |
SOS LAB
|
SOS Lab, a LiDAR development company focusing on core technology for self-driving cars, plans to present its differentiated hybrid LiDAR system, the SL-1SOS LAB's long-range, hybrid scanning design combines the advantages of the widely-used motor scanning system with a solid-state MEMS mirror, and will be offered at a much lower price pointcompared to traditional LiDAR products on the market today. SL-1 is expected to play an important role in the popularization and accessibility of self-driving cars.In addition to the SL-1, SOS LAB offers two additional LiDAR products designed to integrate safe, effective, and affordable LiDAR technology into various industries: the GL-3 for factory automation and robotics, and the TL-3 for security and automatic doors. SOS LAB is also focusing on combining hardware-based sensors and AI-based object recognition and tracking technology using 3D point cloud LiDAR data, and plans to provide LiDAR data space/object recognition solutions for self-driving vehicles.SOS LAB includes jointly developing their hybrid LiDAR with a partner automotive electronic equipment field company, continuing to develop the next generation of Solid-State-LiDAR with global semiconductor companies to overstep the limits of OPA-method LiDAR, and extending the global footprint of SOS LAB to provide the smartest solutions for self-driving and ADAS markets. SOS LAB is planning to enter global markets based on its R&D centers in Seoul and Gwangju and business centers in Silicon Valley. | $14.8M / Series B / Jul 27, 2022 | |
|
Anipen
|
ANIPEN (애니펜) is a Korean 3D content development platform that enables enterprises to develop video communication and entertainment platforms. | $8.4M / Series C / Jul 22, 2022 | |
AUTOCRYPT
|
AUTOCRYPT is the leading player in mobility security technologies. Recognized by TU-Automotive as the Best Auto Cybersecurity Product/Solution of 2019, and shortlisted in 2020 for Automotive Tech Company of the Year, AUTOCRYPT continues to pave the way in transportation and mobility security through a multi-layered, holistic approach. Throughsecurity solutions for V2X/C-V2X, V2G (including Plug & Charge security), in-vehicle security, and Fleet Management, AUTOCRYPT ensures that security is prioritized before vehicles hit the road. | $25.5M / Series B / May 31, 2022 | |
| See all 20 investments → | |||
Co-Investors
Shinhan Venture Investment
4 deals together
BSK Investment
3 deals together
JX Partners
3 deals together
Korea Asset Investment Securities
3 deals together
Korea Development Bank
3 deals together
Quad Asset Management
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
FAQ
What does Ulmus Investment invest in?
Ulmus Investment invests primarily in Biotechnology, Artificial Intelligence and Manufacturing startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ulmus Investment's check size?
Ulmus Investment typically joins rounds of $4.2M–$63M at Series A, $5M–$27M at Series B and $8.4M–$33M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ulmus Investment participates in.
When did Ulmus Investment last invest?
The most recent investment recorded for Ulmus Investment closed in Apr 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
